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1. Introduction 
1.1. Features of cell death 
Until recently cell death occurring in the adult organism 
was believed to be caused mainly by sudden permeabiliza- 
tion of the plasma membrane or lack of energy. This death 
type is termed oncosis/necrosis and is characterized by 
mitochondrial nd cytoplasmic swelling. In the intact or- 
ganism necrosis is accompanied by inflammation in the 
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neighboring tissue [1,2]. The possibility for regulation of 
such death is minimal, since the affected cell will quickly 
be depleted of energy and unable to actively modulate its 
manner of demise. During the last two decades it has 
become increasingly apparent that in most instances cells 
participate actively in effecting their own demise, and that 
deficient regulation of this process is a cause of develop- 
mental abnormalities [3-7], cancer [8,9], and autoimmune 
disease [10-12]. Several recent reviews deal with regulated 
cell death [13-20]. 
The term apoptosis was coined to describe the morpho- 
logical features of regulated cell death [21,22]. In typical 
apoptosis the chromatin becomes marginated and hyper- 
condensed, and the shrinking cell releases fragments ur- 
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rounded by apparently intact plasma membrane. Apoptotic 
cells and their fragments are easily ingested by 
macrophages [23]. Limited cleavage of nuclear DNA [24- 
26] and of rRNA [27] is often, but not invariably [28-33] 
associated with apoptosis. Proteins in apoptotic ells can 
become altered by cross-linking [34,35] or through specific 
cleavage [36-41]. The features of apoptosis may have 
developed to inactivate ndogenous or foreign, e.g., viral, 
potentially harmful macromolecules, and to protect the 
organism against inflammation and autoimmune r actions. 
Regulated cell death may occur without the features of 
apoptosis [42], and one single cell type may display a 
variety of regulated cell death phenotypes, both apoptotic 
and non-apoptotic [43]. 
There is still no universally accepted nomenclature for 
cell death [2,44]. Non-accidental death can be described as 
regulated, active or physiological. Strictly speaking, only 
some cases of regulated cell death satisfy the original 
criteria of apoptosis (see above), but the success of the 
term apoptosis has broadened its use. We propose the term 
'cytoplasmic apoptosis' to describe cytoplasmic condensa- 
tion and cell budding, as observed in enucleated cells 
treated with agents that are apoptogenic for whole cells 
[32,45]. We have not challenged the broad use of the term 
apoptosis by authors referred to in the present review, even 
if the cell death described fails to satisfy all the original 
criteria of apoptosis. 
1.2. Regulation of cell death - a role for protein phospho- 
rylation ?
Active cell death can be staged into a triggering/deci- 
sion phase, a committed (doomed) phase, an execution 
phase, and a final elimination phase. One will expect a 
particularly tight regulation in the triggering/decision 
phase, in which the irrevocable commitment to death is 
decided. In the past most of the focus has been on new 
gene transcription and protein synthesis as regulators of 
cell death [6,13,15,16]. It appears, however, that most, if 
not all, cells have the ability to undergo complete apoptotic 
death independently of new protein synthesis and of their 
position in the cell cycle. This was first pointed out for 
cells treated with protein phosphorylation modulators like 
the Ser/Thr phosphatase inhibitor okadaic acid and the 
broad protein kinase inhibitor staurosporin [29,46]; see also 
Ref. [47]. It has also been known for some time that cells 
can undergo complete apoptotic ell death in response to 
inhibition of protein synthesis [36,48], and that blocking of 
RNA or protein synthesis enhances cell killing through 
receptors belonging to the tumor necrosis factor/nerve 
growth factor receptor superfamily [49-52]. The inherent 
presence of the machinery for death commitment and 
execution means that no factors with cell- or cell cycle- 
specific expression can be universally required for cell 
death commitment or execution. In the cases when cell 
death is triggered by gene expression one will expect he 
new gene products to interact with and modulate the basic 
cell death machinery. This distinguishes the regulation of 
cell death from proliferation control, where a finely tuned 
sequential expression of proteins is required to commit 
cells to proliferate and to drive them through S-phase and 
mitosis [53,54]. It is remarkable that even tumor cell lines 
growing in laboratories for more than a decade under 
conditions which would favor elimination of death-promo- 
ting genes, are still able to undergo apoptotic ell death 
[29,48,55,56]. This suggests that key death-regulating gene 
products may also be essential in promoting survival. In 
this perspective the regulation of cell death becomes a 
question of how the function of existing gene products can 
be turned from survival promotion to death promotion. 
Protein phosphorylation is by far the most common cellu- 
lar mechanism for postsynthetic regulation of protein func- 
tion [57], and is therefore a prime candidate as effector of a 
functional switch of protein function. The function of 
existing proteins can also be modulated allosterically, by 
covalent modification other than phosphorylation, or by 
limited proteolysis [58], which in turn may be modulated 
by protein phosphorylation [59-61]; see also Section 5). 
The role of protein phosphorylation i proliferation, 
metabolism, differentiation, and movement has been stud- 
ied for decades, and is beginning to become elucidated 
[57,62-66]. The role of protein phosphorylation i cell 
death has been much less studied, and the research on this 
topic is still in a primary explorative phase. A major aim 
of the present review is to present he massiveness and 
diversity of the data incriminating protein phosphorylation 
in apoptosis, since the role of protein phosphorylation i  
apoptosis has been doubled [67], and never strongly fo- 
cused upon before. Tyrosine phosphorylation (Section 2) is 
considered first since several survival factors have recep- 
tors linked to tyrosine phosphorylation modulating pro- 
teins. This is followed by a consideration of growth-related 
Ser/Thr kinases (Section 3.1), many of which are acti- 
vated downstream of tyrosine kinase receptor activation in 
signalling cascades. Some of these kinases are specifically 
induced near S-phase or M-phase and can therefore only 
be involved in apoptosis of cells undergoing successful or 
abortive proliferation. Other Ser/Thr protein kinases and 
phosphatases (Sections 3.2-3.5), many with general 
housekeeping functions, will be considered next. These 
enzymes are of interest since even nonproliferating cells 
have the machinery required to respond with apoptosis to 
general perturbants of protein phosphorylation (see above). 
Finally (Section 4), evidence will be presented linking 
selected phosphoproteins to apoptosis and linking selected 
apoptosis-relevant proteins to phosphorylation. 
At the present state of knowledge no attempt will be 
made to present a single unifying hypothesis about he role 
of protein phosphorylation in apoptosis. Rather, the com- 
plexity and heterogenicity of regulated cell death and the 
wealth of protein kinases and protein phosphatases known 
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to exist [68-73] suggest that protein phosphorylation may 
have multiple roles in the control of cell death. 
3. Role of serine / threonine phosphorylation in apopto- 
sis 
2. Role of tyrosine phosphorylation in apoptosis 
Phosphorylation f tyrosme residues is of less abundant 
occurrence in cells than serine and threonine phosphoryla- 
tions. On the other hand tyrosine phosphorylations often 
occur early in signalling cascades, and their effect can 
therefore be strongly amplified via, e.g., Ser/Thr kinases. 
Several survival factor receptors [47,74,75] have intra- 
cellular domains which either have tyrosine kinase activity 
or which interact with tyrosine kinases [76-82]. Tyrosine 
kinase inhibitors can trigge.r apoptosis in survival factor- 
dependent systems, suggesting that the tonic activity of 
tyrosine kinases coupled to ,;uch factors may protect against 
apoptosis [80,83-86]. The notion that tyrosine phospho- 
rylation events are involved in protection of cells against 
death receives further support from the fact that oncogenes 
with tyrosine kinase activity, like v-abl [87-89] and 
bcr/abl [90-93] can protect against apoptosis, and that 
spontaneous apoptosis in germinal center B-cells can be 
arrested by activation of tyrosine phosphorylation coupled 
to the neural growth factor-family member CD40 [94,95]. 
Finally, the src-related tyrosine kinase p56 lck is down-reg- 
ulated in apoptosis of primary thymocytes or thymoma 
cells [96]. 
In cases where tyrosine phosphorylation protects against 
apoptosis one will expect activation of protein tyrosine 
phosphatase to facilitate apoptosis. Protein tyrosine phos- 
phatases have only recently been characterized, but appear 
to belong to a larger family than the Ser/Thr phosphatases 
[71,97-99]. In fact, the expression of the tyrosine phos- 
phatase CD45 [100] increases during T-cell receptor-in- 
duced apoptosis [101] and the tyrosine phosphatase in- 
hibitor phenylarsine oxide induced granulocyte apoptosis 
[86]. One action of survival factors coupled to tyrosine 
kinase is up-regulation of mRNA for the antiapoptotic 
gene bcl-2. Since this up-regulation is blocked by in- 
hibitors of tyrosine kinase, like herbimycin A, it is proba- 
bly mediated by tyrosine phosphorylation [102]. 
In view of the versatility and complexity of the tyrosine 
phosphorylation pathways, it is not surprising that tyrosine 
phosphorylation events are also involved in positive sig- 
nalling of apoptosis. B-cells lacking the tyrosine phos- 
phatase CD45 have increased susceptibility to apoptosis 
[103], and anti-IgM-triggered B-cell apoptosis requires the 
src tyrosine kinase p55 blk [ 104,105]. Apoptosis induced by 
ionizing radiation in human B-lymphocyte precursors cor- 
relates with the activation of an unidentified tyrosine ki- 
nase [106]. Finally, Fas-induced apoptosis is counteracted 
by the tyrosine phosphatase. FAP-1, which interacts with a 
cytosolic apoptosis-associated domain of the Fas receptor 
[107]. 
3.1. Raf kinase, MAPKK, MAPK, and cyclin-dependent 
protein kinases 
Many survival factors also function as growth promot- 
ers or have a signalling system, which at least proximally 
is very similar to that of growth factors [108,109]. Since 
much more is known about protein phosphorylation i
signalling of growth than in signalling of viability, it 
appears of interest o review known relations between 
apoptosis and growth-associated protein kinases and their 
homologs. One way of linking receptor tyrosine kinases to 
Ser/Thr kinase activation is through phosphotyrosine- 
dependent anchoring of Grb2 adapter proteins via SH2 
with subsequent activation of Ras [110], which in turn 
stimulates the Raf Ser/Thr kinase [111]. Interference with 
Ras activation by displacement of Grb2 by its negatively 
acting relative Grb3-3 can lead to apoptosis [112]. A role 
of Raf kinase in protecting against cell death is also 
suggested by the fact that enforced expression of the v-raf 
oncogene protects against myeloid cell apoptosis due to 
interleukin-3 withdrawal [113]. 
It has been suggested that the Raf kinase may act 
anti-apoptotically through interaction with the Bcl-2 pro- 
tein with which it synergizes in preventing apoptosis [114]. 
Another possibility is that the survival-promoting effect of 
active Raf kinase is mediated through phosphorylation a d 
activation of MAPKK, which is believed to mediate the 
growth-promoting effect of Raf kinase. MAPKK is a dual 
specificity kinase which phosphorylates the mitogen acti- 
vated kinase (MAPK) on both tyrosine and threonine 
residues. A survival-promoting role of MAPK is suggested 
in pheochromocytoma PC12 cells, where the survival fac- 
tor NGF activates MAPK via a Ras-dependent pathway. In 
NGF-deprived sympathetic neurons cAMP activates MAPK 
and rescues the cells from apoptosis [115]. The role of 
MAPK in suppressing apoptosis is not straightforward, 
however, since activation of MAPK via a Ras-independent 
pathway [116,117], failed to protect against NGF depriva- 
tion. MAPK activates p90 rsk/s6Kinase and MAPKAP [118], 
whose substrates include heat shock proteins and transcrip- 
tion factors. It is probable that activation of MAPK will 
have a different effect, depending on the cell content of 
p90 rsk/s6Kinase, MAPKAP, their substrates, and the activity 
of other kinases and phosphatases acting on the same 
substrates. It is also probable that the survival-promoting 
phosphorylation pathways may prove harder to elucidate 
than the growth-promoting pathways, which lead to the 
induction of cyclin genes, which is an easily measurable 
parameter. Since blocking of transcription or translation 
offers at least transient protection against death due to 
deprivation of survival factors, gene induction is expected 
to have a less prominent role in survival signalling than in 
growth signalling. 
190 B.T. Gjertsen, S.O. DCskeland/Biochimica etBiophysica Acta 1269 (1995) 187-199 
The proliferation-promoting effect of growth factors 
may be mediated through the phosphorylation f nuclear 
transcription factors by MAPK and of $6 kinases. These 
transcription factors are presumably involved in the induc- 
tion of D and E cyclins, controlling the G I /S  transition of 
the cell cycle. Cyclin A acts in the S-phase [119,120]. The 
cyclins activate the catalytic subunits of cyclin-dependent 
kinase (cdk) when the latter is phosphorylated ona crucial 
threonine residue and dephosphorylated on an inhibitory 
tyrosine residue [121]. Since these kinases and their associ- 
ated proteins are expressed or active only in proliferating 
cells they cannot explain apoptosis induced in resting cells 
[29,122,123]. They are, however, candidates for mediating 
death in actively proliferating cells, and some of their 
effects, like mitotic chromatin condensation and internal 
membrane redistributions, are at least superficially repro- 
duced in apoptosis [67,124-126]. Evidence incriminating 
the cyclin-dependent proliferation-associated kinases in 
apoptosis is activation of cyclin A-dependent Cdk2 and 
cdc2 kinases in HeLa cell apoptosis induced by caffeine, 
6-dimethylaminopurine, staurosporine or okadaic acid 
[127]. Cytotoxic T-cell protease-induced apoptosis required 
premature (before the G2/M phase of the cell cycle) 
activation of target cell p34 cdc2 kinase [128]. Activation of 
p34 cdc2 is also necessary for cisplatin-induced apoptosis 
subsequent to G2 arrest [129]. 
It is also possible that the proliferation-associated ki- 
nases have apoptosis-promoting homologs expressed in 
resting cells or that they become aberrantly expressed in 
some cases of programmed cell death. Cyclin D1 was 
induced in postmitotic neurons undergoing apoptosis due 
to NGF deprivation [123]. CDK6 P~xsLRE and CDK4 PsK-J3 
associate with cyclin D1 [130], and belong to a subgroup 
of the p34 ~dc2 protein kinase family proposed to have a 
role in apoptosis [ 131]. The retinoblastoma antigen (Rb) is 
able to bind and inhibit cyclin D, an effect reversed by 
hyperphosphorylation [132,133]. A role for non-hyper- 
phosphorylated Rb could be to protect against high level of 
cyclins which otherwise may trigger apoptosis through 
premature p34 c~c2 activation [123,128]. In quiescent fi- 
broblasts, the 57 kDa phosphoprotein statin is suggested to
block the early G I phase phosphorylation f the Rb pro- 
tein [38]. One kinase candidate for phosphorylating Rb in 
this cell cycle phase is the cdc-2 related PITALRE, which 
is expressed in all parts of the cell cycle [134]. 
In conclusion, the available vidence suggests that the 
kinases involved in the signalling of proliferation can have 
a role also in apoptosis, but details of such a role are 
lacking. At present he available evidence suggests that 
such kinases are less pivotal in the control of cell demise 
than cell proliferation. 
3.2. Lipid second messenger-dependent pro ein kinases 
(ceramide-activated PK and PKC) 
The enzyme sphingomyelinase cl aves phospholipid nto 
ceramide and phosphocholine and can be activated by 
ligand-induced trimerization of members of the NGF/TNF 
receptor superfamily [135-137]. This receptor family has 
members involved in the induction of cell death, like the 
T-cell associated Fas-antigen (APO- 1/CD95) [ 17,51,138- 
140] and the generally expressed 75 kDa and 55 kDa [141] 
forms of the TNF/lymphotoxin-a receptor. Other mem- 
bers, like the low-affinity NGF-receptor, mediate cell sur- 
vival signals [142,143]. Ceramide has been termed the 
'killer lipid' [144,145]. It mimics the apoptogenic effect of 
TNF-c~ in a number of cell lines [146,147] and may be a 
mediator of radiation-induced ndothelial cell apoptosis 
[148]. Ceramide is a specific activator of a membrane- 
bound Ser/Thr protein kinase [149] which in turn activates 
the mitogenic Raf/MAPKK/MAPK pathway [149,150]. 
Ceramide also activates a cytosolic phosphatase [151] of 
the PP2A-family and the phorbol ester-insensitive PKC-~" 
[152,153]. The ceramide and APO-1/CD95 pathways 
would be expected to provide new insight into apoptogenic 
protein phosphorylation pathways ince their action is fast 
and apparently direct, being independent of new protein 
synthesis or the nucleus [32,51,52]. 
The involvement of the phospholipid-dependent ki ase 
(PKC) family in diverse cell functions and its role as 
modulator of other signalling systems, has made it the 
subject of more research articles than any other kinase 
during the last decade. This is also true in the field of 
apoptosis research, most studies being based on the use of 
the phorbol ester TPA as protein kinase C activator. The 
PKC family comprises at least 11 isoforms [154-156]. All 
isozymes require phosphatidylserine for activation, but 
differ with respect o requirement for Ca 2+ and ability to 
be activated by phorbol esters. The c~, /3I, /3II and y 
isozymes need Ca 2+ and either diacylglycerol r phorbol 
ester (e.g., TPA) for maximum activity. The isozymes 6, 
e, r/ and 0 are CaZ+-independent, and the 'atypical' 
isozymes ( ~', A, and /x) are independent of both Ca 2 + and 
diacylglycerol/phorbol ester [157]. 
Studies aimed at single PKC isozymes have implicated 
PKC-/3 and PKC-6 as mediators of differentiation-associ- 
ated apoptosis in a human leukemia cell line [158-161]. 
The ability to differentiate and demise by apoptosis of a 
PKC-/3-deficient HL-60 cell line was regained after prim- 
ing with vitamin D, which also restored the PKC-/3 ex- 
pression [162]. Further evidence for PKC-/3 involvement 
in apoptosis i  provided by the correlation between apopto- 
sis and PKC-/3 up-regulation and translocation from nu- 
cleus to cytoplasm in neutrophils, promonocytic U937 
cells and tonsil epithelial cells [163,164]. Finally, the 
preferential PKC-/3 activator 12-deoxyphorbol 13-phenyl- 
acetate 20-acetate (Doppa) induced apoptosis in U937 cell 
[164]. Mouse thymocyte apoptosis triggered by glucocorti- 
coid is associated with increased particulate PKC-e activ- 
ity [ 165]. 
PKC-stimulating phorbol esters can protect against 
apoptosis due to radiation [ 166-169], glucocorticoid [ 170], 
or deprivation of growth factors [171-176], suggesting that 
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protection against apoptosis may be one mechanism 
whereby phorbol esters act as tumor promoters [166]. On 
the other hand phorbol esters enhanced the radiosensitivity 
of a pre-T-cell line [168], enhanced apoptosis due to serum 
withdrawal in a neural cell line [177], and induced apopto- 
sis of immature mouse thymocytes in suspension [178]. 
TPA was less efficient as apoptosis inducer for mouse 
thymocytes grown in intact thymic lobes [160]. The dual 
and cell- or species-dependent ffects of crude PKC acti- 
vators like TPA (see above) argue against a fundamental 
role of massive, general PKC activation in the induction or 
execution of apoptosis. Rather, one would expect altered 
PKC activity to be one of many inputs modulating the 
cell's decision to undergo apoptosis. One signalling path- 
way inyolving PKC and with potential as apoptosis modu- 
lator consists of phosphoinositide 3-kinase, PKC-~', and 
p70 s6Kinase. It is believed to signal from activated growth 
fac tor  receptors  in para l le l  w i th  the 
Ras/Raf /MAPKK/MAPK pathway [157,179], and has 
recently been shown to be involved in the rescuing of 
PC12 cells by nerve growth factor [180]. 
3.3. cAMP-dependent protein kinase 
Intracellular effects of cAMP in eukaryotes are believed 
to be mediated exclusively via the cAMP-dependent pro- 
tein kinase I and II (cAK type I and II). The activity of 
these enzymes is restrained by regulatory (RI or RII) 
subunits, whose inhibition is relieved upon cAMP binding 
[181,182]. cAK has a proven role as inducer of apoptosis 
in $49 lymphoma cells and IPC-81 promyelocytic cells. 
The systems are different, elevated cAMP slowly leading 
to G1 arrest and secondary cytolysis in $49 cells [183,184] 
and to rapid transcription- and translation-dependent cell 
fragmentation i IPC cells [185]. In either case cAMP 
resistance is provided by rescuing mutations in the cAMP- 
binding sites of the RI subunit [186,187]. Requirement for 
the catalytic subunit of cAK is demonstrated by cAMP 
resistance in $49 cells deficient in catalytic subunit 
[ 188,189] and by microinjection of purified catalytic sub- 
unit of C into IPC cells, which gives the same apoptotic 
morphology as cAMP increase [190]. cAMP-induced tran- 
scription- and translation-dependent apoptosis is also 
demonstrated in mature T-lymphocytes [191]. In the intact 
developing animal epithelial cell death coincides with an 
increase in cAMP level at the time of fusion of the palatal 
shelf [ 192]. Physiological involution of the mammary gland 
is associated with elevated nuclear activity of cAK and 
modulation of DNA binding for the putative cAK sub- 
strates Fos/JunD and Oct--1 [193]. 
In the above examples cAMP may be the prime inducer 
of apoptosis, but cAMP nmy also facilitate apoptosis pri- 
marily induced by other agents, like glucocorticoid-induced 
thymocyte apoptosis [194,195]. cAMP enhances the apop- 
totic effect of tumor necrosis factor-a (TNF) in thymo- 
cytes [196] and in the human mammary carcinoma cell line 
MCF-7 [197]. Macrophages infected by Bordetella pertus- 
sis undergo apoptosis if simultaneously exposed to in- 
creased cAMP [198]. 
In some situations elevation of cAMP can protect against 
apoptosis. T-cell hybridoma cells treated with antibodies 
against he CD3 receptor excrete interleukin-2, stop prolif- 
eration and undergo apoptosis. The chain of events leading 
to cell death can be arrested by cAMP analog given up to 
1 h after T cell activation [199]. Elevated cAMP rescues 
the bone marrow-derived cell line D32 from apoptosis due 
to withdrawal of interleukin-3 [200]. Similarly, cAMP 
protects neural growth factor-deprived sympathetic neu- 
rons from death [201-203]. Miillerian inhibitory substance 
induces regressions of the Miillerian ducts in male rats, a 
process inhibited by cAMP analogs [204]. 
The relevant protein substrates mediating the effect of 
cAK on apoptosis have not been identified. Since the 
apoptogenic effect of cAMP in some systems is coupled to 
prior inhibition of DNA replication [43,183], it would 
appear worthwhile to test whether it involves actions on 
Raf or p27, as in other systems where cAMP inhibits DNA 
replication [120,121,205-208]. 
3.4. Nucleic acid-, stress-, and Ca2+-activated protein 
kinases 
Apoptotic ell death can be induced by default, as when 
cells are deprived of survival factors [47], by external 
signals or genetic programs, or can be induced as a result 
of the cell-sensing damage of itself. In this section some 
kinases will be considered which are in a position to sense 
damage to macromolecules or cell 'stress' and therefore 
are candidates for conveying apoptosis-promoting si nals 
in the cell. 
It is established that DNA damage, in many cases via 
p53, can cause cells to undergo apoptosis, presumably to 
prevent he multiplication of cells with altered genetic 
information. The DNA-activated protein kinase is stimu- 
lated by nanomolar concentrations of DNA containing 
nicks or larger single-stranded gaps, staggered or blunt- 
ended fragments and circular DNAs [209], which can 
occur in cells with damaged DNA or exposed to illegiti- 
mate viral DNA. It is a nuclear Ser/Thr kinase able to 
phosphorylate a number of DNA-binding regulatory pro- 
teins like Spl, Fos, Jun, Myc, p53 and RNA polymerase II 
[210,211]. The DNA-activated kinase is in a position to 
signal DNA damage, but it is still not known whether it 
acts to link DNA damage and apoptosis. 
Illegitimate double-stranded RNA may be produced 
during virus infection, and apoptosis with its associated 
cleavage of RNA [27,212,213] would be the ultimate 
defense against spread of virus from infected to nonin- 
fected cells. The double-stranded RNA-activated p68 ki- 
nase is a tumor suppressor that can be induced by interfer- 
ons [214]. An important arget is the a-subunit of the 
eukaryotic elongation factor 2, whose phosphorylation in- 
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hibits the initiation of translation. HeLa cell apoptosis 
could be induced either by overexpression f p68 kinase or 
by infection with a vaccinia virus strain lacking the E3L 
inhibitor of p68 kinase [215]. In interleukin 3-deprived 
hematopoietic cells undergoing apoptosis there was a par- 
allel activation of p68 kinase and inhibition of protein 
synthesis [216]. 
The apoptosis inducers cycloheximide, moderate heat, 
and TNF have in common the ability to activate a newly 
discovered stress-activated p54 c-Jun kinase related to the 
MAPK family [217]. It will be of interest to know if this 
kinase is essential for the apoptosis induced by the above 
agents. In the case of apoptosis induced by cycloheximide 
at concentrations sufficient o inhibit protein synthesis a
role of the p54 c-Jun kinase will require either that the 
kinase has additional substrates or that c-Jun has actions 
that are independent of protein synthesis. 
Rise of free intracellular Ca 2÷ has been associated with 
accidental cell death with the morphology of necrosis, but 
the role of Ca 2÷ and its main intracellular eceptor 
calmodulin is less straightforward in apoptosis [20,218]. A 
protective role has been proposed for the Ca2+/calmodu - 
lin-dependent kinase II in neurons exposed to ischemia or 
extended neuronal depolarization [219-221]. This is based 
on the down-regulation f the enzyme when the cells start 
to die, but it cannot be excluded that the kinase may have a 
positive role in the development of apoptosis, the down- 
regulation being secondary to death [222]. The 
Ca2+/calmodulin-dependent protein kinase II appears to 
be necessary for okadaic acid- and microcystin-induced 
hepatocyte apoptosis [29,223]. We have found that specific 
inhibitors of Ca2+/calmodulin-dependent protein kinase II 
can protect hepatocytes against microcystin-induced death 
commitment until 2 min before cytoplasmic apoptosis. But 
the same inhibitors protect against typically apoptotic hro- 
matin margination and condensation even when given to 
death-committed cytoplasmically apoptotic ells (R. Bee, 
O.K. Vintermyr and S.O. D0skeland, manuscript in prepa- 
ration). This indicates that one set of phosphorylation 
events committed the cells to death and cytoplasmic apop- 
tosis, but that additional phosphorylation events are re- 
quired to induce chromatin hypercondensation. This obser- 
vation challenges the view that cell death commitment 
activates proteolytic enzymes, which subsequently effect 
nuclear chromatin condensation i dependently of protein 
phosphorylation [67]. 
3.5. Roles of phosphoserine / phosphothreonine-preferring 
protein phosphatases in apoptosis 
The phosphorylation state of a target protein is the net 
result of the opposing actions of protein kinases and 
phosphoprotein phosphatases. The phosphatases are 
broadly classified into phosphoserine/phosphothreonine 
preferring (PP) or phosphotyrosine preferring (PTP), al- 
though some overlap in specificity exists. An example is 
the Ser/Thr phosphatase PP2A, which in the presence of 
the viral proteins middle-T/small-T acts as a tyrosine 
phosphatase [224]. The Ser/Thr protein phosphatases (PP) 
can broadly be categorized into those highly sensitive to 
the microbial inhibitors microcystin, okadaic acid and 
calyculin A, like PP1 [225], PP2A [226], PP3 [227], 
PP4/PPX [228], and PP5/PYY [229], the less sensitive 
enzymes like the Ca2+/calmodul in-dependent 
PP2B/calcineurin [226,230], and the insensitive nzymes 
like PP1C. 
Inhibition of PP by okadaic acid and related substances 
may be a general way of triggering apoptosis through the 
cell's pre-existing machinery, i.e., without need for the 
induction of new cell death genes or for ongoing protein 
synthesis [29,43]. Primary hepatocytes, GH 3 pituitary ade- 
noma cells, MCF-7 mammary carcinoma cells, neuroblas- 
toma cells, and IPC-81 promyelocytic cells all underwent 
apoptosis in response to okadaic acid [29]. Similar findings 
have been reported for other leukemia cells [40,231,232], 
hamster embryo cells [233], U937 histiocytic lymphoma 
cells, BT20 mammary carcinoma cells, LNCap prostatic 
cancer cells [234], MB-231 and AU-565 mammary carci- 
noma cells [235], thymocytes [27,96], endothelial cells 
[27], and insect cells [236]. The induction of apoptosis by 
phosphatase inhibitors suggests that protein phosphatases 
may protect against cell death. Protein phosphatase activity 
seems required for the maintenance of light-stimulated 
photoreceptor cells since light can induce degeneration i  
the okadaic acid-treated crab retina [237] and in the retina 
of mutant Drosophila melanogaster with disrupted func- 
tion of a Ser/Thr protein phosphatase [238]. An attractive 
possibility is that apoptosis can also be induced by endoge- 
nous phosphatase inhibitors. It has been proposed that TNF 
treatment of fibroblasts may inhibit the endogenous PP2A 
activity, since the same proteins became hyperphosphory- 
lated in response to TNF and low concentrations of okadaic 
acid [239]. 
The altered phosphorylation pattern associated with 
death-signalling in apoptotic ells has been termed 'dys- 
phosphorylation' [39]. Presumably there is no invariant 
phosphorylation pattern signalling apoptosis. In primary 
hepatocytes Ca2+/calmodulin-dependent protein kinase II 
activity appears to be required for induction of apoptosis 
by okadaic acid and microcystin [223]. In U937 cells 
myosin light chain kinase activity may be required for 
TNF/okadaic acid effects [234]. In promyelocytic IPC-81 
cells and human neuroblastoma cells inhibitors of either 
Ca2+/calmodulin-dependent protein kinase II or myosin 
light chain kinase were unable to counteract okadaic acid- 
induced apoptosis (data not shown). These results indicate 
that the phosphoproteins mediating okadaic acid-induced 
apoptosis are different or at least substrates for different 
kinases in various cell types. It is of interest hat the 
apoptotic features (degree Of DNA and 28S rRNA frag- 
mentation, degree of nuclear fragmentation) differed in one 
cell type, depending on type and concentration of phos- 
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phatase inhibitor (okadaic acid or calyculin A) used, sug- 
gesting that the cell has available multiple death options 
that can be activated by subtly different perturbations of
protein phosphorylation [43]. 
The apparent ability of okadaic acid to rescue cells from 
apoptosis induced by other agents [240-242] remains to be 
explained. In some cell systems the explanation can be that 
the phosphatase-inhibitor-induced death is less conspicu- 
ous with regard to cell and DNA fragmentation than death 
induced by other agents, leading to pseudorescue from 
apoptosis by okadaic acid [,43]. In other systems death may 
be signalled by okadaic acid-sensitive phosphatases, one 
candidate being a ceramide-activated phosphatase [136]. 
PP2B/calcineurin may also be involved in positive sig- 
nalling of apoptosis. The PP2B inhibitor cyclosporin A 
rescued B-cells from undergoing apoptosis in response to 
cross-linking of cell surface immunoglobulins or increased 
[Ca2+] i [243]. Cyclosporin A also protected thymocytes 
and T-cell hybridoma cells against activation-induced 
apoptosis [244]. Finally, the cellular level of PP2B activity 
correlated positively with the ability of T-cell hybridomas 
to undergo T-cell receptor/CD3-triggered apoptosis [245]. 
4. Phosphorylation-regulated proteins involved in apop- 
tosis 
The action of the apoptosis-associated kinases and 
phosphatases described above are mediated by phospho- 
proteins. Increased phosphorylation f hitherto unidentified 
proteins has been reported in apoptosis [39,246]. The 
identification of apoptosis-relevant phosphoproteins and 
elucidation of their function appear to be of prime impor- 
tance to advance our understanding of how protein phos- 
phorylation modulates apoptosis. This section will review 
evidence that a number of proteins already incriminated in
apoptosis can be phosphorylated, suggesting that some of 
the phosphoproteins involved in apoptosis have already 
been identified, and that clues of their role can be gained 
from further study of their phosphorylation i  apoptotic 
cells. The fact that so many of the proteins implicated in 
apoptosis are phosphoproteins serves the additional pur- 
pose of supporting the contention that protein phosphoryla- 
tion is important in apoptosis, although the link between 
phosphorylation a d apoptosis remains to be elucidated in 
most cases referred to below. 
Cytoskeletal components are obvious targets in apopto- 
sis as evidenced by the frequent occurrence of cell round- 
ing, loss of anchorage, and often cell fragmentation, u- 
clear envelope disintegration a d hypersegregation of cyto- 
plasm [247]. Loss of integrin-mediated contact with fi- 
bronectins can be sufficient o declench apoptosis in cer- 
tain anchorage-dependent c lls, and is presumably linked 
to decreased activity of the focal adhesion kinase, which is 
activated by tyrosine phosl3horylation [248]. The apoptosis 
induced by the PP inhibitors okadaic acid and calyculin A 
is associated with altered cytoskeletal structure and phos- 
phorylation [233,249,250], one of the primary targets being 
intermediate filaments. Vimentin, a major component of 
intermediate filaments, becomes hyperphosphorylated in 
intact cells treated with calyculin A [249-254], and the 
association of vimentin with nuclear lamins is lost upon 
treatment with okadaic acid [255]. This phosphorylation 
occurs in the C-terminal part of vimentin [233,256] which 
interacts with signalling enzymes like phospholipase C and 
PKC [256,257]. In glutamate-induced death of astrocytes, 
vimentin is phosphorylated by Ca2+/calmodulin-depen - 
dent protein kinase II [258]. 
Normal p53 facilitates growth arrest [120,259-261] and 
apoptosis [262-268] in response to, e.g., minimal DNA 
damage [269-271], which may explain why p53 is so 
commonly down-regulated or deleteriously mutated in can- 
cer cells [272-274]. p53 has several phosphorylation sites 
[260] and is tightly associated with casein kinase II, which 
phosphorylates p53 at a C-terminal residue [275]. The 
trans-activation domain is phosphorylated by DNA- 
activated kinase [276] and casein kinase I, and one site in 
the DNA binding region is phosphorylated by p34 ¢dc2 
kinase [277]. p53 appears to be dephosphorylated by
okadaic acid-sensitive phosphatase(s) [278]. Hyperphos- 
phorylation of p53 is believed to attenuate transactivation 
[279], but the exact functional consequences of p53 phos- 
phorylation are still uncertain [280]. 
The transcription factors c-Myc and Max, the former 
triggering and the latter inhibiting apoptosis if overex- 
pressed [281,282], are regulated by phosphorylation 
[283,284]. Phosphorylation sites in c-Myc are often found 
mutated in Burkitt's lymphoma (65%) and plasmacytomas 
(30%), and these regions are associated with transcrip- 
tional activation and apoptosis [285]. 
Bcl-2 is well known for its ability to protect against 
apoptosis [286], but its mechanism of action has been 
elusive. Bcl-2 is a phosphoprotein [287], and its phospho- 
rylation was increased in cells rescued from apoptosis by 
treatment with either interleukin-3 or bryostatin-1 [288]. 
GAP-43 (neuromodulin/B-50/P-57/protein F1) s sub- 
ject to PKC catalyzed [289] and ganglioside-stimulated 
[290] phosphorylations. GAP-43 has been implicated in the 
regulation of olfactory epithelium death [291] and its 
mRNA is abundant in interdigital mesenchyme undergoing 
programmed cell death [292]. In Alzheimer's disease, neu- 
rons demonstrate d creased phosphorylation f GAP-43 in 
membrane fractions from areas with high neurofibrillary 
tangle density [293]. 
The heat shock family of proteins are induced in re- 
sponse to stress and would be expected to protect cells 
against damage. One member of this protein family, hsp-27, 
is particularly prone to phosphorylation, being a substrate 
for the MAPK activated MAPKAP as well as for other 
growth-related kinases [294]. The phosphorylation f hsp- 
27 is increased by the potential apoptosis-inducers TNF 
and okadaic acid [39,239,295]. 
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Nucleolin is a phosphoprotein operating as a shuttle 
between cytoplasm and nucleus and may be involved in 
the hypercondensation of chromatin occurring in mitosis 
and in apoptosis, ince it acts synergistically with phospho- 
rylated histone 1 to condense chromatin [296]. Nucleolin is 
phosphorylated by casein kinase 2 and a cdc-2-related 
kinase [297]. It is a target for granzymes, which are 
apoptosis-triggering proteases ecreted by cytotoxic T- 
lymphocytes and natural killer cells [298,299]. The poten- 
tial apoptosis-inducers TNF and okadaic acid led to in- 
creased phosphorylation f nucleolin in fibroblasts [239]. 
5. Conclusions and future directions 
The amount of data pointing to regulatory roles of 
protein phosphorylation in cell death is so massive that the 
major question appears no more to be if protein phospho- 
rylation affects cell death, but rather how this is accom- 
plished. One major unanswered question is whether one 
basic molecular machinery is responsible for apoptosis, 
and in that case how this is affected by protein phospho- 
rylation. Promising systems to probe effects of phospho- 
rylation on the putative basic apoptosis machinery appear 
to be those in which agents known to affect protein 
phosphorylation i duce apoptosis rapidly and without the 
requirement of new protein synthesis. Examples are cells 
susceptible to soluble Fas-ligand [17,140,300], cytotoxic 
T-cells [300-302], or phosphorylation-perturbing toxins of 
type okadaic acid, calyculin A, and staurosporine, which 
are rapidly acting, general inducers of non-necrotic ell 
death [29,39,43,45]. In addition to analysis of wild-type 
cells, the more general availability of cells with genetically 
altered or 'knocked-out' kinases or phosphatases will help 
pinpoint he phosphorylation pathways involved. 
Since phosphorylation is reversible and apoptosis is 
irreversible, it is probable that phosphorylation at some 
point facilitates irreversible damage to macromolecules, 
like proteolysis or limited polynucleotide degradation, 
which in turn commits cells to death. There is considerable 
evidence that limited proteolysis is involved in apoptosis 
[67,303-308], and it appears teleologically reasonable that 
this regulatory mechanism is more prominent in a demis- 
ing cell than in a proliferating cell. Limited proteolysis i
observed in apoptosis induced by phosphatase inhibitors 
[40]. There are ample possibilities for interactions between 
protein phosphorylation and proteolysis in death regula- 
tion. Limited proteolysis can modulate kinase activity [61]. 
Phosphorylation f proteins can alter their susceptibility o 
existing protease activities [59]. Phosphorylation can acti- 
vate proteases directly [60], or through modulation of 
ubiquitination [309]. 
Whereas an error allowing a cell to commence prolifer- 
ation can be corrected by subsequent elimination of that 
cell's progeny by apoptosis, commitment to apoptosis 
cannot be amended. It would therefore be reasonable to 
assume that the regulation of apoptosis is even more 
complex than that of proliferation. This means that most of 
the regulatory mechanisms involved in apoptosis remain to 
be worked out, and it is hoped that progress in the field 
will be fast enough to rapidly make the present review 
become obsolete. 
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